Semaglutide Significantly Improves Chronic Kidney Disease

Source link :

STOCKHOLM — Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown significant benefits in preventing major kidney disease, cardiovascular events, as well as mortality in patients with chronic kidney disease (CKD) and type 2 diabetes in the landmark FLOW trial. “This is the first trial that’s specifically asked the question of whether this class of […]

Author : News Health

Publish date : 2024-05-24 23:33:05

Copyright for syndicated content belongs to the linked Source.